Neuburgh Advisers’s 10x Genomics TXG Stock Holding History

Neuburgh Advisers’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$343K	Buy	+6,798	New	+$376K	0.01%	555

Other funds holding TXG

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

JCM

JS Capital Management New York $109M AUM 34.13% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Neuburgh Advisers's TXG Position: Q3 2019 in Review

Neuburgh Advisers opened a new position in 10x Genomics (TXG) in Q3 2019: 6,798 shares worth $343K. The stake represents 0.01% of the portfolio and ranks #555 among its holdings.

92 funds tracked by Wall St. Rank hold TXG as of Q3 2019.

Neuburgh Advisers held 6,798 shares of 10x Genomics worth $343K as of Q3 2019.
10x Genomics was a new Neuburgh Advisers position in Q3 2019.
10x Genomics made up 0.01% of Neuburgh Advisers's portfolio in Q3 2019, its #555 holding.
92 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.